|
Phenytoin dosing guidelines |
|||||||||||||||||||||||||
|
This initial program provides some general dosage
guidelines based on population averages for the Michaelis-Menten
parameters (Km and Vmax). The recommendations do not take into account
the following: (1) existence of interacting drugs (3) inter-patient
variability (3) existing disease states which may significantly
alter the eventual therapeutic dose. The program uses a maintenance dose of 4 to 6
mg/kg for all adults < 60 years old. The elderly (defined as
age>60) on the other hand, exhibit a saturation of metabolism at
dosages that are usually 20 % lower than in younger patients. For this
reason, the program recommends initial dosages of 3-4 mg/kg in this age
group. (Note: many studies have found only slight variations in Km with
regards to age, however, Vmax has been found to decline steadily with
age--most notably after the 6th decade). The program
also calculates an "adjusted dose" for reported levels when
the serum albumin level is < 4.5 g/dl. The program accomplishes this
by utilizing the Sheiner-Tozer equation: C adj = Creported
/(0.2 x serum albumin) + 0.1. MD (mg/day) = [ ( Vmax x Css) / (S)(F)(Km + Css ]
|
|||||||||||||||||||||||||
|
Other Equations |
|||||||||||||||||||||||||
It is important to remember that since phenytoin's elimination is a saturable process, and clearance decreases with increasing concentrations, the steady state concentration is NOT proportional to the maintenance dose (e.g. a non-linear relationship exists). Also, the half-life has little value in estimating the time to steady state. |
|||||||||||||||||||||||||
|
Additional Information |
|||||||||||||||||||||||||
|
Note: program uses adjusted body weight for all calculations. Loading Dose (IV):
10 - 20 mg/kg . Recommended infusion rate for
adults: 40-50 mg/min. Elderly (>65): Recommended infusion rate: 20-25
mg/min. Oral loading: Give in 3 to 4 divided doses at q2h intervals. (Divided doses increase bioavailability as well as decrease potential for GI side effects such as N&V). The maximum single oral dose should not exceed 400 mg in order to minimize GI side effects and also increase absorption (decrease likelihood of concretions). Sampling: 18 to 24 hours after the loading dose, and then every 5 to 7 days to assess trend. Average time to steady state: 10-14 days. Half-life: 7 to 42 hours (average = 24 hours). Conversion to once daily dosing: Consider only after a divided dose regimen on extended phenytoin capsules is established. (Only extended release Dilantin caps are recommended for once daily administration.) A patient should never receive a once daily dose of elixir or injection as maintenance. When do you start the maintenance dose? The maintenance dose is started 18-24 hours after the loading dose. Capsules/injection= 92% phenytoin (sodium salt). Elixir/tabs=100% phenytoin. Equation used to estimate the dose required to increase current level to normal range if subtherapeutic: = [0.7 x IBW x (15 - current level) ] / 0.92* * (if capsules/injection used) Adjusted phenytoin concentration if low serum albumin = measured total concentration / [ (0.2 x albumin) + 0.1]
|
|||||||||||||||||||||||||
|
Cautions |
|||||||||||||||||||||||||
|
(1) Always remember that because
phenytoin's elimination is dose-dependent ("capacity
limited"), that small increases in dosage can produce
disproportionate increases in serum levels (possibly 3 to 4 fold). (3) Changes in the daily maintenance dose should be made in small increments (30-100mg maximum). Sample serum levels 7 to 10 days following each dosage change to assess the trend. Steady state is usually achieved after 10-14 days, however, it may be much longer than this in some patients. (4) Once therapeutic steady state levels are achieved, periodic levels based on clinical judgment should be obtained. Some studies have found fluctuations in steady state serum concentrations > 150% in patients receiving the same daily maintenance dose. All factors must be considered: addition of interacting drugs, changes in absorption (eg enteral feeding + oral administration of phenytoin), concomitant disease state(s) which may alter phenytoin kinetics, etc. (5) Changes in albumin levels or the binding affinity of phenytoin to albumin must be taken into account (total phenytoin levels are of little value if significant changes occur). Determination of the free concentration is recommended in these patients with a target concentration of 1-2 mcg/ml. Factors which may reduce albumin levels include: hepatic cirrhosis, cachexia, burns, malnutrition, and nephrotic syndrome. Factors which may decrease the affinity of phenytoin to albumin or cause displacement include: interacting drugs, increased bilirubin, renal failure ...). The following equations can be used to adjust the serum concentrations based on either reduced albumin levels or presence of renal failure (crcl < 10 ml/min). Some studies have found considerable underestimation of serum levels while using these equations in some patients. Again, the most accurate assessment can be made by obtaining the actual unbound (free) level. The adjustment equations are estimations, and should be considered exactly that. Hypoproteinemia Renal
failure:
|
|||||||||||||||||||||||||
|
References |
|||||||||||||||||||||||||
|
|